Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)

Market Cap	2.33B +23.8%
Revenue (ttm)	209.51M +49.6%
Net Income	-100.02M
EPS	-0.91
Shares Out	109.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,522,954
Average Volume	1,226,134
Open	22.14
Previous Close	21.93
Day's Range	21.10 - 22.19
52-Week Range	18.56 - 33.67
Beta	0.86
RSI	62.68
Earnings Date	Apr 24, 2026

About Jiangsu CoWin Biotech

Jiangsu CoWin Biotech Co., Ltd. engages in the research and development, production, and sale of biological products in China. The company provides molecular diagnostic raw material enzymes, nucleic acid collection and protection agents, nucleic acid extraction and purification kits, molecular diagnostic testing reagents, etc. It also offers medical device products, nucleic acid collection and protection, PCR, RT-PCR, and qPCR products, molecular diagnosis, isothermal amplification, nucleic acid mass spectrometry, next generation sequencing, nu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 770
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688426

Financial Performance

In 2025, Jiangsu CoWin Biotech's revenue was 193.52 million, an increase of 53.74% compared to the previous year's 125.88 million. Losses were -107.41 million, -31.68% less than in 2024.